Related Experiment Video
Updated: Mar 22, 2026
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
MicroRNA-29a: A potential biomarker in the development of intracranial aneurysm
Wei-Hua Wang1, Yun-Hua Wang2, Li-Li Zheng1
1Central Laboratory, Liaocheng People's Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng 252000, PR China.
Aim:
To identify serum microRNA-29a (miR-29a) level in patients with intracranial aneurysm and its role in the development of intracranial aneurysm (IA).
Methods:
Case group included 165 IA patients hospitalized in the department of neurosurgery between January 2010 and January 2012 while control group enrolled 220 healthy volunteers. Morning fasting blood samples were collected from peripheral vein. RT-PCR was used for miR-29a detection. Receiver Operating Characteristic (ROC) curve was drawn. Survival curves were drawn for survival analysis with Kaplan-Meier method and Long-rank test was conducted. MiR-29a expression Glasgow Prognosis Score (GOS) was used for prognosis scaling. Multivariate Cox proportional hazards regression analysis was performed for prognosis analysis. Results Cases had significantly higher miR-29a expressions than controls (P<0.05). ROC curve analysis indicated that miR-29a expression in IA had high effectiveness in IA diagnosis. Close associations were identified between miR-29a expression and rupture, Hunt-Hess level and surgical timing (all P<0.05). GOS strongly associated with history of hypertension, aneurysm location, rupture, Hunt-Hess level and miR-29a expression. Patients with low miR-29a expression had longer disease-free survival (DFS) and overall survival (OS) than those with high miR-29a expression (both P<0.05). MiR-29a expression, tumor aneurysm, rupture and Hunt-Hess were risk factors to the prognosis of IA (all P<0.05).
Conclusion:
MiR-29a may be closely related to IA development and therefore could be a useful predicator of IA prognosis, providing a new target for IA therapy.
Insights
Serum microRNA-29a (miR-29a) levels are elevated in patients with intracranial aneurysms (IA). Higher miR-29a expression correlates with poorer prognosis, suggesting its potential as a diagnostic and therapeutic target for IA.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Intracranial aneurysm (IA) is a significant cause of cerebrovascular disease.
- Identifying reliable biomarkers for IA diagnosis and prognosis is crucial for effective management.
Purpose of the Study:
- To determine serum microRNA-29a (miR-29a) levels in patients with IA.
- To investigate the role of miR-29a in IA development and its prognostic value.
Main Methods:
- Serum samples from 165 IA patients and 220 healthy controls were analyzed for miR-29a expression using RT-PCR.
- Receiver Operating Characteristic (ROC) curve analysis was employed for diagnostic accuracy.
- Survival analysis (Kaplan-Meier) and Cox regression were used to assess prognostic factors.
Main Results:
- Significantly higher serum miR-29a levels were observed in IA patients compared to controls (P<0.05).
- miR-29a expression demonstrated high effectiveness in IA diagnosis via ROC analysis.
- Elevated miR-29a was associated with aneurysm rupture, Hunt-Hess grade, and poorer prognosis, including shorter disease-free and overall survival.
Conclusions:
- Serum miR-29a may play a role in the development of intracranial aneurysms.
- miR-29a serves as a potential biomarker for IA diagnosis and prognosis.
- Targeting miR-29a could offer a novel therapeutic strategy for IA.
